About Boston Scientific
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and PI businesses. Its Rhythm Management segment consists of CRM and EP businesses. Its MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its interventional cardiology products include Drug-Eluting Coronary Stent Systems, Core Coronary Technology, Intravascular Imaging and Structural Heart Therapy. Its peripheral products include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: Health Care Equipment
- Exchange: NYSE
- Symbol: BSX
- CUSIP: 10113710
- Previous Close: $24.48
- 50 Day Moving Average: $24.32
- 200 Day Moving Average: $23.00
- 52-Week Range: $16.82 - $25.65
- Trailing P/E Ratio: 99.12
- Foreward P/E Ratio: 17.45
- P/E Growth: 1.56
- Market Cap: $33.75B
- Outstanding Shares: 1,362,104,000
- Beta: 1.06
- Net Margins: 4.14%
- Return on Equity: 23.70%
- Return on Assets: 8.60%
Companies Related to Boston Scientific:
- Debt-to-Equity Ratio: 0.80%
- Current Ratio: 0.90%
- Quick Ratio: 0.64%
What is Boston Scientific's stock symbol?
Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."
Where is Boston Scientific's stock going? Where will Boston Scientific's stock price be in 2017?
25 brokers have issued 1-year target prices for Boston Scientific's stock. Their predictions range from $21.00 to $33.00. On average, they expect Boston Scientific's share price to reach $25.99 in the next twelve months.
When will Boston Scientific announce their earnings?
Boston Scientific is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.
What are analysts saying about Boston Scientific stock?
Here are some recent quotes from research analysts about Boston Scientific stock:
Needham & Company LLC analysts commented, "This morning BSX filed an 8-K noting that it announced a voluntary removal of all of its Lotus transcatheter aortic valve replacements (TAVR) from commercial and clinical sites due to premature release of a pin connecting Lotus to the delivery system. This appears to be related to the issue that led to a November suspension of Lotus Edge in the EU and that BSX thought it had resolved. BSX expects to re-launch Lotus in 4Q17 and now expects a 6 month delay to US Lotus Edge launch. BSX had previously guided to $300M of structural heart sales in 2017; we think around $120M of this is at risk (~$0.03 of EPS)." (2/23/2017)
- Northland Securities analysts commented, "The implications for Edwards now are a longer runway without BSX truly being on the market, potential questions arising about product design / reliability of the Lotus Valve. More importantly, Edwards now has a chance to pick up incremental share in Europe. We remain strong buyers of EW." (2/23/2017)
According to Zacks Investment Research, "Amid challenging economic conditions, a competitive environment and severe currency headwinds, Boston Scientific posted mixed third-quarter 2016 results, with earnings in line with the Zacks Consensus Estimate and revenues ahead of the mark. On a positive note, backed by a strong global team, perfect execution of long-term strategic plans including portfolio expansion, globalization efforts and investments into faster growth markets, the company posted 9% organic growth. The efficient plan execution will further result in fulfilment of its margin leverage and EPS goals. However, we are concerned with the still sluggish defibrillator performance within the company’s core CRM segment. Nevertheless we believe, Boston Scientific will overcome the hiccups with its efforts to strenthen core businesses and invest in new technologies and markets. The company’s Urology business is also gaining traction." (10/31/2016)
Credit Suisse Group analysts commented, "We are increasing our target price to $97 (from $84) on the continuing growth momentum." (7/29/2016)
Who owns Boston Scientific stock?
Boston Scientific's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (12.60%), State Street Corp (4.51%), Artisan Partners Limited Partnership (3.13%), Janus Capital Management LLC (3.05%), Orbimed Advisors LLC (1.21%) and Putnam Investments LLC (0.34%). Company insiders that own Boston Scientific stock include Charles J Dockendorff, Daniel J Brennan, David A Pierce, Ernest Mario, Jeffrey B Mirviss, John Bradley Sorenson, John E Abele, John E Sununu, Joseph Michael Fitzgerald, Karen Prange, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Timothy A Pratt and Wendy Carruthers.
Who sold Boston Scientific stock? Who is selling Boston Scientific stock?
Boston Scientific's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace LLP, Dimensional Fund Advisors LP, Fred Alger Management Inc., Orbimed Advisors LLC, Systematic Financial Management LP, Zurich Insurance Group Ltd FI and Employees Retirement System of Texas. Company insiders that have sold Boston Scientific stock in the last year include Daniel J Brennan, David A Pierce, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Karen Prange, Keith D Dawkins, Kevin J Ballinger, Michael F Mahoney, Michael P Phalen and Timothy A Pratt.
Who bought Boston Scientific stock? Who is buying Boston Scientific stock?
Boston Scientific's stock was acquired by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Putnam Investments LLC, Alyeska Investment Group L.P., State Street Corp, Asset Management One Co. Ltd., Russell Investments Group Ltd., Artisan Partners Limited Partnership and Renaissance Technologies LLC. Company insiders that have bought Boston Scientific stock in the last two years include Charles J Dockendorff and John E Abele.
How do I buy Boston Scientific stock?
Shares of Boston Scientific can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Boston Scientific stock cost?
One share of Boston Scientific stock can currently be purchased for approximately $24.78.